Replication-Competent Herpes Simplex Virus Vector G207 and Cisplatin Combination Therapy for Head and Neck Squamous Cell Carcinoma

Neoplasia

Volumn 1, Issue 2, 1999, Pages 162-169

  Chahlavi, Ali ^a   Todo, Tomoki ^a   Martuza, Robert L ^a   Rabkin, Samuel D ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cisplatin; Gene therapy; Head and neck cancer; Herpes simplex virus; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; GENE VECTOR; GENETICS; HEAD AND NECK TUMOR; HERPES SIMPLEX VIRUS; HUMAN; METHODOLOGY; MOUSE; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; SQUAMOUS CELL CARCINOMA; TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; SIMPLEXVIRUS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0033140039     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900016     Document Type: Article

References (42)

1. Parker SL, Tong T, Bolden S, and Wingo PA (1997). Cancer statistics, 1997. CA Cancer J Clin 47, 5-27.
2. Carey TE (1994). Head And Neck Tumor Cell Lines. In Atlas of Human Tumor Cell Lines. R. J. Hay, J.-G. Park and A. Gazdar, Eds. Academic Press, San Diego. 79-120.
3. Hong WK, and Bromer R (1983). Chemotherapy in head and neck cancer. N Engl J Med 308, 75-79.
4. Clark JR, and Dreyfuss AI (1991). The role of cisplatin in treatment regimens for squamous cell carcinoma of the head and neck. Semin Oncol 18, 34-48.
5. The Department of Veterans Affairs Laryngeal Cancer Study Group (1991). Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 325, 1656-1657.
6. Hong WK, Shapshay SM, Bhutani R, Craft ML, Ucmakli A, Yamaguchi KT, Vaughan CW, and Strong MS (1979). Induction chemotherapy in advanced squamous head and neck carcinoma with high-dose cisplatinum and bleomycin infusion. Cancer 44, 19-25.
7. Kish JA, Weaver A, Jacobs J, Cummings G, and Al-Sarraf M (1984). Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 53, 1819-1824.
8. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H. Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, Chemg N, Dalton T, Burroughs J, and Rozeneweig M (1992). A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10, 257-263.
9. Tupchong L, Scott CB, Blitzer PH, Marcial VA, Lowry LD, Jacobs JR, Stetz J, Davis LW, Snow JB, Chandler R, Kramer S, and Pajak TF (1991). Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: Long-term follow-up of RTOG Study 73-03. Int J Radiat Oncol Biol Phys 20, 21-28.
10. Kotwall C, Sako K, Razack MS, Rao U, Bakamjian V, and Shedd DP (1987). Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg 154, 439-442.
11. Haraf DJ, Weichselbaum RR, and Vokes EE (1996). Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol 7, 913-918.
12. Mineta T, Rabkin, SD, Yazaki T, Hunter WD, and Martuza RL (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1, 938-943.
13. Yazaki T, Manz HJ, Rabkin SD, and Martuza RL (1995). Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 55, 4752-4756.
14. Toda M, Rabkin SD, and Martuza RL (1998). Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 9, 2177-2185.
15. Liverpool Head and Neck Oncology Group (1990). A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 61, 311-315.
16. Forastiere AA, and Urba SG (1995). Experimental therapeutic approaches for recurrent head and neck cancer. Cancer Treat Res 74, 263-281.
17. Williams SD, Velez-Garcia E, Essessee I, Ratkin G, Birch R, and Einhom LH (1986). Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate. Cancer 57, 18-23.
18. Boviatsis EJ, Park JS, Sena-Esteves M, Kramm CM, Chase M, Efird JT, Wei MX, Breakfield XO, and Chiocca EA (1994). Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 54, 5745-5751.
19. Miyatake S, Martuza RL, and Rabkin SD (1997). Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 4, 222-228.
20. Chase M, Chung RY, and Chiocca EA (1998). An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 16, 444-448.
21. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, and Kim JH (1998). A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 9, 1323-1333.
22. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, and Kim DH (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3, 639-645.
23. Toda M, Martuza RL, Kojima H, and Rabkin SD (1998). In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus vector combination induces local and systemic antitumor activity. J Immunol 160, 4457-4464.
24. Andreansky S, He B, van Cott J, McGhee J, Markert JM, Gillespie GY, Roizman B, and Whitley, RJ (1998). Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 5, 121-130.
25. Advani SJ, Sibley GS, Song PY, Hallahan DE, Kataoka Y, Roizman B, and Weichselbaum RR (1998). Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther 5, 160-165.
26. Nielsen LL, Lipari P, Dell J, Gurnani M, and Hajian G (1998). Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 4, 835-846.
27. Kanamori Y, Kigawa J, Minagawa Y, Irie T, Oishi T, Shimada M, Takahashi M, Nakamura T, Sato K, and Terakawa N (1998). A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. Eur J Cancer [A] 34, 1802-1806.
28. Teicher BA, Holden SA, Kelly MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD, and Frei E (1987). Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum (II). Cancer Res 47, 388-393.
29. Kurihara N, Kubota T, Hoshiya Y, Otani Y, Watanabe M, Kumai K, and Kitajima M (1996). Antitumor activity of cis-diamminedichloroplatinum (II) against human tumor xenografts depends on its area under the curve in nude mice. J Surg Oncol 61, 138-142.
30. Newkirk K, Heffem J, Sloman-Moll E, Sessions RB, Rasmussen AA, Andrews PA, and Cullen KJ (1997). Glutathione content but not gamma glutamyl cysteine synthase mRNA expression predicts cisplatin resistance in head and neck cancer cell lines. Cancer Chemother Pharmacol 40, 75-80.
31. Vokes EE, Weichselbaum RR, Lippman SM, and Hong WK (1993). Head and Neck Cancer. W Engl J Med 328, 184-194.
32. Rao DN, Shroff PD, Chattopadhyay G, and Dinshaw KA (1998). Survival analysis of 5595 head and neck cancers-results of conventional treatment in a high-risk population. BrJ Cancer 77, 1514-1518.
33. Bi W, Kim YG, Feliciano ES, Pavelic L, Wilson KM, Pavelic ZP, and Stambrook PJ (1997). An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. Cancer Gene Ther 4, 246-252.
34. Wilson KM, Stambrook PJ, Bi WL, Pavelic ZP, Pavelic L, and Gluckman JL (1996). HSV-tk gene therapy in head and neck squamous cell carcinoma. Enhancement by the local and distant bystander effect. Arch Otolaryngol Head Neck Surg 122, 746-749.
35. Schuller DE, McGuirt WF, Krause CJ, McCabe, BF, and Pflug BK (1979). Increased survival with surgery alone vs. combined therapy. Laryngoscope 89, 582-594.
36. Jesse RH, and Lindberg RD (1975). The efficacy of combining radiation therapy with a surgical procedure in patients with cervical metastasis from squamous cancer of the oropharynx and hypopharynx. Cancer 35, 1163-1166.
37. Pinto AL, and Lippard SJ (1985). Binding of the antitumor drug cis-diammine-dichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta 780, 167-180.
38. Pinto AL, and Lippard SJ (1985). Sequence-dependent termination of in vitro DNA synthesis by cis-and trans-diamminedichloroplatinum (II). Proc Natl Acad Sci USA 82, 4616-4619.
39. Heiger-Bemays WJ, Essigmann JM, and Lippard SJ (1990). Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. Biochemistry 29, 8461-8466.
40. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, and Chaney SG (1994). Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54, 3500-3505.
41. Snyder MB, Saravolatz LD, Markowitz N, Pohlod D, Taylor RC, and Ward SG (1987). The in-vitro and in-vivo efficacy of cisplatin and analogues in the treatment of herpes simplex virus-II infections. J Antimicrob Chemother 19, 815-822.
42. Le Gac NT, Villani G, and Boehmer PE (1998). Herpes simplex virus type-1 single-strand DNA-binding protein (ICP8) enhances the ability of the viral DNA helicase-primase to unwind cisplatin-modified DNA. J Biol Chem 273, 13801-13807.